Form D · Biotechnology
ENB Therapeutics, Inc.
New York, NY · CIK 0001753420
Offering snapshot reported Oct 3, 2023 · SEC filing
- Reported sold
- $225K Offering amount: $1M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 22, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 3, 2023 | Initial | $225,000 | No comparison | 3 | SEC filing |
| Jan 11, 2021 | Initial | $1,282,500 | No comparison | 3 | SEC filing |
| Feb 13, 2020 | Amendment | $8,094,584 | $5,800,012vs Sep 21, 2018 | 17 | SEC filing |
| Sep 21, 2018 | Initial | $2,294,572 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-493707
Source: Form D, filed Oct 3, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stuart Hwang | Director |
| Sumayah Jamal | Director, Executive |
| Fumitaka Mori | Director |
| Walter Olesiak | Director |
| Barbara Schilberg | Director |
| Albert Sokol | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Launchlabs 430 E 29th St., 14 Th Floor
New York, NY, 10016
New York, NY, 10016